Navigation Links
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Date:9/19/2007

acture Risk in Postmenopausal Women with Osteoporosis: Results from a Three-Year, Randomized, Placebo- and Active-Controlled Clinical Trial," which enrolled 7,492 postmenopausal women between the ages of 55 and 85 with moderate to severe osteoporosis, bazedoxifene showed significant risk reduction, compared with placebo, for new vertebral fractures. Specifically, the three-year incidences of new vertebral fracture were 2.3 percent, 2.5 percent, 2.3 percent and 4.1 percent in the bazedoxifene 20 mg, bazedoxifene 40 mg, raloxifene 60 mg and placebo groups, respectively.

In addition, a subgroup analysis of 1,782 women at higher risk for fracture showed that bazedoxifene significantly reduced the incidence of non- vertebral fracture. In particular, the non-vertebral fracture incidence was 3.0 percent, 3.8 percent, 5.9 percent and 6.3 percent in bazedoxifene 20 mg, bazedoxifene 40 mg, raloxifene 60 mg and placebo groups, respectively, with a risk reduction of 46 percent, compared with placebo, when both bazedoxifene doses were combined.

About Osteoporosis

According to the National Osteoporosis Foundation, the number of women of menopausal age who have osteoporosis or are at risk for developing the disease will increase from almost 30 million in 2002 to nearly 41 million by 2020. Osteoporosis causes approximately 1.5 million fractures each year in the United States alone, and the risk of fracture significantly increases in women usually after age 50. Non-vertebral fractures are more common than vertebral fractures and account for an estimated 300,000 hip and 250,000 wrist fractures, in addition to an estimated 250,000 fractures at other non- vertebral sites such as the clavicle, humerus, pelvis and leg.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, o
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)...  IP Shakti, LLC, today announced that it has changed ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... identity signifies our transformation into a company focused on patent ... patent claim validity." ... Shield™ platform, the Company commenced a corporate re-branding initiative in ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... SARcode Corporation presented data today for their lead investigational ... trial, subjects receiving SAR 1118 demonstrated a reduction in ... as compared to placebo. These data were part of ... Vision and Ophthalmology (ARVO) Annual Meeting held in Fort ...
... 3, 2011 At the Board of Directors meeting held ... per share. The dividend is payable on June 15, 2011 ... About Sigma-Aldrich: Sigma-Aldrich is a leading ... to Improve the Quality of Life. Its chemical and biochemical ...
Cached Medicine Technology:SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 2SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 3
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor Day weekend, the last ... on September 22nd this year). For IT security personnel, it should also mark the ... prove far more costly than a simple headache. , Joe Caruso, founder and CEO-CTO ...
(Date:8/29/2015)... Houston, TX (PRWEB) , ... August 29, 2015 ... ... settlement allows the company to freely market and sell Arterosil and Arterosil HP, ... Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the ...
(Date:8/28/2015)... ... 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth ... are applying for, they are unable to pass the initial drug test and therefore ... policies in order to be able to hire long-term, skilled talent. (1) Will Wesch, ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... ... ... “ Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, which ... Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the ... movement from beginning to end. , Businesses benefit greatly from having the ability to ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... ... facility, is announcing the launch of a state-of-the-art new website designed to mirror the ... the weight loss surgery process, and the latest tools of the web, the new site ... ...
... ... ), a privately held consulting company, announced today its marketing ... System solutions. Veracord,s comprehensive validation and compliance expertise extends the ... to compete in the FDA regulated industry. Together, Veracord and ...
... , , CHICAGO, Aug. ... scaly skin and rashes. It is commonly known as "the itch ... not known, it appears to result from a complex interaction of factors ... , Scratching the affected area can lead to more ...
... , , , ... Georgetown University Medical Center study find Kefir, a probiotic-rich drink, may ... experiencing health problems. In the study, the sickest children got the ... "We are happy to see that the 10 strains of good ...
... , WASHINGTON, Aug. 3 ... to Planned Parenthood President Cecile Richards to debate the question -- ... for abortion coverage and taxpayer funded abortions ? , ... Huffington Post, Planned Parenthood,s president states that the plan ...
... , , August is ... HARRISBURG, Pa., Aug. 3 Department of Health Secretary Everette ... National Immunization Awareness Month. , , "Recommended ... sure you and your family are up-to-date on these immunizations ...
Cached Medicine News:Health News:Tennessee's New Life Center for Bariatric Surgery Launches Comprehensive Website Reaching out to Sufferers of Morbid Obesity 2Health News:Tennessee's New Life Center for Bariatric Surgery Launches Comprehensive Website Reaching out to Sufferers of Morbid Obesity 3Health News:Tennessee's New Life Center for Bariatric Surgery Launches Comprehensive Website Reaching out to Sufferers of Morbid Obesity 4Health News:Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 2Health News:Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 3Health News:Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 4Health News:Five Questions About Eczema 2Health News:Five Questions About Eczema 3Health News:Five Questions About Eczema 4Health News:Five Questions About Eczema 5Health News:Kefir, a Probiotic-Rich Drink, May Benefit Specific Groups of Children 2Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: